Browsing by Author "Cabrera García, Daniel Alejandro"
Now showing 1 - 16 of 16
Results Per Page
Sort Options
- ItemAngiotensin-(1-7) Prevents Skeletal Muscle Atrophy Induced by Transforming Growth Factor Type Beta (TGF-beta) via Mas Receptor Activation(2016) Abrigo, Johanna; Simon, Felipe; Cabrera García, Daniel Alejandro; Cabello Verrugio, Claudio Alejandro
- ItemCholic acid and deoxycholic acid induce skeletal muscle atrophy through a mechanism dependent on TGR5 receptor(2020) Abrigo, J.; Gonzalez, F.; Aguirre, F.; Tacchi, F.; Gonzalez, A.; Meza, M. P.; Simon, F.; Cabrera García, Daniel Alejandro; Arrese, Marco; Karpen, S.; Cabello Verrugio, Claudio Alejandro
- ItemCTGF/CCN-2 over-expression can directly induce features of skeletal muscle dystrophy(2011) Morales France, María Gabriela; Cabello Verrugio, Claudio Alejandro; Santander Sepúlveda, Cristian Andrés; Cabrera García, Daniel Alejandro; Roel Goldschmeding; Brandan, Enrique
- ItemDecorin Interacts with Connective Tissue Growth Factor (CTGF)/CCN2 by LRR12 Inhibiting Its Biological Activity(2011) Vial, C.; Gutiérrez Pérez, Jaime Agustín; Santander Sepúlveda, Cristian Andrés; Cabrera García, Daniel Alejandro
- ItemEmerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon(2024) Arnold Álvarez, Jorge Ignacio; Idalsoaga Ferrer, Francisco Javier; Diaz Piga, Luis Antonio; Cabrera García, Daniel Alejandro; Barrera Álvarez, Francisco Benjamín; Arab Verdugo, Juan Pablo; Arrese Jiménez, Marco AntonioPurpose of Review Metabolic dysfunction–associated steatotic liver disease (MASLD) and its aggressive form, metabolic dysfunction-associated steatohepatitis (MASH), are highly prevalent and can lead to fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure. Currently, there is no approved pharmacological treatment for MASLD. In this review, we aim to summarize recent data on therapeutic agents under study in phase 2 and 3 trials.Recent FindingsBuilding on a better understanding of MASLD/MASH pathophysiology, a myriad of drugs has been developed. Recent results from clinical trials show promise, with some candidates demonstrating positive outcomes in phase 3 trials that are predictably expected to be approved in the near future. Notably, resmetirom, a thyroid receptor β agonist, is likely to be approved in 2024.SummaryIn the coming years, results from several landmark trials will be available and will likely provide options to prevent progression to cirrhosis and adverse liver outcomes in patients with MASLD/MASH.
- ItemGlypican-1 regulates myoblast response to HGF via Met in a lipid raft-dependent mechanism: Effect on migration of skeletal muscle precursor cells(2014) Gutiérrez Pérez, Jaime Agustín; Cabrera García, Daniel Alejandro; Brandan, Enrique
- ItemHepatic fatty acid profile in mice with nonalcoholic fatty liver disease using magnetic resonance spectroscopy(2019) Xavier, Aline Carvalho da Silva; Zacconi, Flavia C. M.; Cabrera García, Daniel Alejandro; Fuenzalida, Karen; Andía Kohnenkampf, Marcelo EdgardoNonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of intracellular fatty acids in the liver. The only method to confirm the stage of this disease is the biopsy, but it is invasive and risky to patients. The idea of defining a classifier using magnetic resonance spectroscopy (MRS) emerges due to the need to find a way to replace biopsy with a non-invasive method that can classify NAFLD based on the chemical structure of fatty acids stored in the liver. The purpose of this study is to investigate and compare the composition of fatty acids to the metabolites signals in MRS in NAFLD mice liver at 2 time-point during the progression of the disease. A group of C57BL/6 mice was fed with high-fat diet for one month (N = 8) and for three months (N = 6). First, we made a histological analysis to the liver. Then, we analysed the fatty acids with gas chromatography (GC) and MRS. As a result, the histological analysis showed the progression of fat content, and the GC analysis detected a different fatty acid liver composition during the progression of NAFLD along with an increase of the total fat storage in the liver. The differences in the composition fatty acids are also reflected in the MR Spectrum, which could have clinical potential for monitoring the progression of this disease with a non-invasive technique.
- ItemInhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2)(2013) Morales, M.; Cabrera García, Daniel Alejandro; Céspedes Fierro, Carlos Mauricio.; Vio Lagos, Carlos P.
- ItemIntrahepatic fatty acids composition as a biomarker of NAFLD progression from steatosis to NASH by using 1H-MRS(2019) Xavier, Aline Carvalho da Silva; Zacconi, Flavia C. M.; Gaínza Kunstmann, Constanza Mikela; Cabrera García, Daniel Alejandro; Arrese, Marco; Uribe Arancibia, Sergio A.; Sing-Long C., Carlos A.; Andía Kohnenkampf, Marcelo EdgardoNon-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world and it is becoming one of the most frequent cause of liver transplantation. Unfortunately, the only available method that can reliably determine the stage of this disease is liver biopsy, however, it is invasive and risky for patients. The purpose of this study is to investigate changes in the intracellular composition of the liver fatty acids during the progression of the NAFLD in a mouse model fed with Western diet, with the aim of identify non-invasive biomarkers of NAFLD progression based in H-1-MRS. Our results showed that the intracellular liver fatty acid composition changes as NAFLD progresses from simple steatosis to steatohepatitis (NASH). Using principal component analysis with a clustering method, it was possible to identify the three most relevant clinical groups: normal, steatosis and NASH by using H-1-MRS. These results showed a good agreement with the results obtained by GC-MS and histology. Our results suggest that it would be possible to detect the progression of simple steatosis to NASH using H-1-MRS, that has the potential to be used routinely in clinical application for screening high-risk patients.
- ItemLiver Dysfunction as a Novel Player in Alzheimer's Progression : Looking Outside the Brain(2019) Estrada, L.D.; Ahumada, P.; Cabrera García, Daniel Alejandro; Arab Verdugo, Juan Pablo
- ItemN-Acetyl Cysteine Attenuates the Sarcopenia and Muscle Apoptosis Induced by Chronic Liver Disease(2020) Abrigo, J.; Marin, T.; Aguirre, F.; Tacchi, F.; Vilos, C.; Simon, F.; Arrese Jiménez, Marco; Cabrera García, Daniel Alejandro; Cabello Verrugio, Claudio Alejandro
- ItemNovel and optimized strategies for inducing fibrosis in vivo: Focus on Duchenne Muscular Dystrophy(2014) Pessina, P.; Cabrera García, Daniel Alejandro; Morales France, María Gabriela; Riquelme Illanes, Cecilia Angélica
- ItemObeticholic acid: expanding the therapeutic landscape of NASH(2015) Arrese Jiménez, Marco; Cabrera García, Daniel Alejandro; Barrera Martínez, Francisco José
- ItemRole of Oxidative Stress as Key Regulator of Muscle Wasting during Cachexia(2018) Abrigo, J.; Elorza, A. A.; Riedel, C. A.; Vilos, C.; Simon, F.; Cabrera García, Daniel Alejandro; Estrada, L.; Cabello Verrugio, Claudio Alejandro
- ItemTGF-β requires the activation of canonical and non-canonical signalling pathways to induce skeletal muscle atrophy(2018) Ábrigo, Johanna; Campos, Fabian; Simon, Felipe; Riedel, Claudia; Cabrera García, Daniel Alejandro; Vilos, Cristian; Cabello Verrugio, Claudio Alejandro
- ItemTransforming growth factor type beta (TGF-β) requires reactive oxygen species to induce skeletal muscle atrophy(2016) Abrigo, Johanna; Rivera, Juan Carlos; Simon, Felipe; Cabrera García, Daniel Alejandro; Cabello Verrugio, Claudio Alejandro